Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.96 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TET3 | O43151 | 1/20 | 0.53 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.53 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.53 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.53 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.53 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.53 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19249602 | 1.00 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL66387 | 1.00 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1042420 | 1.00 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3811046 | 0.98 | AKR1C1 (0.92) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL65167 | 0.98 | AKR1C1 (1.00) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| Water SCHEMBL3811044 | 0.96 | AKR1C1 (0.88) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8315894 | 0.96 | AKR1C1 (0.96) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1667343 | 0.93 | AKR1C1 (0.91) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL8105149 | 0.91 | AKR1C1 (0.88) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL11665752 | 0.91 | AKR1C1 (0.88) | AKR1C1HDAC4KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239867-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-03-26 | — | — | US | disclosed |
| US-10022352-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180162842-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-06-14 | — | — | US | disclosed |
| US-9758510-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-12 | — | — | US | disclosed |
| US-9732080-B2 | Azaindole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-08-15 | — | — | US | disclosed |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | HOFFMANN-LA ROCHE INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | disclosed |
| US-8207193-B2 | Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists | ASTRAZENECA AB (SE) | 2012-06-26 | — | — | US | disclosed |
| US-20100029713-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-2029541-B1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2009-12-30 | — | — | EP | disclosed |
| EP-2094694-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| EP-2029541-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOXYLIC ACIDS | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008059239-A1 | NOVEL COMPOUNDS 514 | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059239-A1 | NOVEL COMPOUNDS 514 | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059245-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008059245-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2007113155-A1 | PROCESS FOR PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC Β-ARYL OR HETEROARYL CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | HOFFMANN-LA ROCHE INC. | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029713-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | AKR1C1 649/4885HDAC4 3084/4885KMT2A 2440/4885 |
| US-20130253201-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS | AHR, CYP8B1, ADRA2C | AKR1C1 176/4885HDAC4 2415/4885KMT2A 1178/4885 |
| US-20180162842-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | AKR1C1 1131/4885HDAC4 2932/4885KMT2A 4313/4885 |
| US-20070232653-A1 | Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids | AHR, CYP8B1, ADRA2C | AKR1C1 176/4885HDAC4 2415/4885KMT2A 1178/4885 |
| US-10022352-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | AKR1C1 1131/4885HDAC4 2932/4885KMT2A 4313/4885 |
| US-20130005695-A1 | QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | AKR1C1 650/4885HDAC4 3135/4885KMT2A 2333/4885 |
| US-10239867-B2 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | AKR1C1 1131/4885HDAC4 2932/4885KMT2A 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.